Name Title Contact
   
Jack G. Chirikjian, PhD

Professor and Director

Email: jgc@georgetown.edu
Phone: 202-687-2160

   
Vasna Nontanovan, MS

Associate Director

Email: vn5@georgetown.edu
Phone: 202-687-6136

   
Karen Brotherton-Julien, MS

Program Manager

Email: kmb24@georgetown.edu
Phone: 202-687-1501

   
You-Shin Chen, PhD

Instructor

Email: yc239@georgetown.edu
Phone: 202-687-8951

   
Robert Donahue, MA

Laboratory Manager

Email: rd802@georgetown.edu
Phone: 202-687-8549

   
Khuyen Mai, MS

Instructor

Email: kdn4@georgetown.edu
Phone: 202-687-6787

   
Aradhana Massey, MS

Research and Education Specialist

Email: am3229@georgetown.edu
Phone: 202-687-6815

   
Ken Wasserman, PhD

Assistant Professor

Email: kw546@georgetown.edu
Phone: 202-687-2241

Faculty

 
Name Title Expertise
   
Richard Ascione, PhD  

Associate Professor, Adjunct

Molecular Medicine

CEO, President OnkoLogix USA LTD and ImmunoLogix LTD USA and CSO of OnkoRx in Beijing China
Director, Equity Research, Fairlook Investment Advisors LLC.
MD/PhD from New York University - Bellevue
OnkoLogix LTD and OnkoRx are innovative cancer therapeutic companies that are currently developing novel anti-cancer biologics for Gastric Cancer and other malignancies. ImmunoLogix LTD is a unique Biotech Company developing innovative approaches to developing vaccine and immunologicals for a variety of infectious diseases, including the Pandemic Influenzas and other viral diseases. Prior to this activity Dr. Ascione was active in the Biopharmaceutical Industry as: Consultant and CSO for ViRexx Medical Corp., Vice President, Research, of Aphton Biopharmaceutical Corporation, Prior to his Industry career, Dr. Ascione was a tenured professor in the Department of Experimental Oncology and served as the Associate Director of the Center for Molecular and Structural Biology at the Hollings Cancer Center and the Medical University of South Carolina, respectively, in Charleston, South Carolina. Prior to his academic career, Dr. Ascione was with the National Cancer Institute (NCI) of the National Institutes of Health (NIH), where he served as Deputy Chief of NCI's Laboratory of Molecular Oncology working on the pioneering investigations of the role of oncogenes in human malignancies.

   
Amrita Cheema, PhD

Professor

Metaballomics

   
Elliott Crooke, PhD

Professor & Chair

Biochemistry

   
You-Shin Chen, PhD

Instructor

Biochemistry

   
Robert Donahue, MA

Instructor

Molecular Methods

   
Lee Eiden, PhD  

Professor, Adjunct

Drug Discovery

Chief of the Section on Molecular Neuroscience in the National Institute of Mental Health Intramural Research Program of the National Institutes of Health
Ph.D. in Pharmacology from The University of Kansas
Lee E. Eiden is the Chief of the Section on Molecular Neuroscience in the National Institute of Mental Health Intramural Research Program of the National Institutes of Health, Bethesda, Maryland. He received his B.A. in Chemistry from Northwestern University in Evanston Illinois, and Ph.D. in Pharmacology from The University of Kansas, and was a Staff Fellow, PRAT Fellow, and Senior Staff Fellow in the NIMH Intramural Research Program before joining the faculty as a Principal Investigator and Chief of the Unit on Cell Biology in 1987, and Chief of the Section on Molecular Neuroscience in 1992. His work at the NIH has focused on stimulus-secretion-synthesis coupling, characterization of the vesicular and secretory proteins mediating chemically coded neurotransmission, including chromogranin A, VMAT1, VMAT2, and VAChT and signaling pathways underlying neuropeptide-mediated stress responses. More recently, the laboratory has been involved in microarray- and bioinformatics-aided gene discovery within neuropeptide-dependent stress-activated cellular signaling pathways in the central nervous system, and has characterized a novel cAMP sensor for neuroendocrine cell-specific GPCR-initiated signaling to the MAP kinase ERK. Dr. Eiden is a member of the editorial boards of Peptides, Cellular and Molecular Neurobiology, and Science Signaling.
Find out more about Lee Eiden.

   
Jessica Jones, PhD

Associate Professor

Biochemistry

   
Usha Kasid, PhD

Professor

Tumor Biology

   
Edward Kisailus, PhD  

Professor, Adjunct

Immunology

Professor of Biology at Canisius College
Ed Kisailus is a professor of biology at Canisius College in Buffalo, NY where he has been teaching in the Biology Department for over 38 years. Ed has taught Immunobiotechnology (BCHB-525) at Georgetown University since 1998, since the inception of the biotechnology program. His research interests include in vivo herbal supplement induced apoptosis in the promyelocytic leukemia cell line HL-60; and in carbohydrate-binding specificity analysis of lectins (carbohydrate-binding proteins) purified from normal and neoplastic human tissues. Most of his research has been perormed at Roswell Park Cancer Center in Buffalo, NY. Ed enjoys sailing on Lake Erie where he also crews (main sheet and traveler) on a 39’ C&C during race season.

   
Ivica Labuda, PhD  

Assistant Professor, Adjunct

Food Biotechnology

Adjunct Professor at Georgetown University
Ivica Labuda, PhD is an adjunct Professor at Georgetown University lecturing on food biotechnology, fermentations and international biotechnology.  She is also a founder of consulting company Biokeys for Flavors, LLC and a skincare company NovaKera, LLC.  Earlier Ivica worked for companies such as Kraft, Givaudan, Cultor-Danisco and Pepsi at various research and management roles.  Ivica holds 13 patents, 23 peer-review publications and several book chapters.

   
Evagelia Laiakis, PhD  

Assistant Professor

Oncology

Dr. Laiakis is currently an Assistant Professor at Georgetown University Lombardi Comprehensive Cancer Center. Her research focuses on the effects of ionizing radiation (terrestrial and space related) on normal tissue, biodosimetry, and for radiotherapy purposes, with emphasis on metabolic changes through the use of metabolomics and mass spectrometry. Her expertise is in small molecule biomarker development to elucidate mechanisms of disease, including cancer and inflammation.

   
Mary Beth Martin, PhD

Professor

Breast Cancer

   
Khuyen Mai, MS

Intructor

Biochemistry

   
Dean Rosenthal, PhD

Associate Professor

Biochemistry

   
Joseph Shiloach, PhD  

Associate Professor, Adjunct

Biologics Production

Head, Biotechnology Core, NIDDK, NIH
The Biotechnology Core specializes in large-scale production and purification of biological materials from various sources to advance research in fields such as vaccine development, drug development, and structural biology. To achieve this goal, the laboratory integrates two main functions: (1) production of biologics, conducted in a multipurpose, state-of-the-art production facility, and (2) research and process development related to solving biological production issues by utilizing physiological, molecular biology, and technical approaches.
Find out more about Joseph Shiloach here.

   
Cynthia Simbulan-Rosenthal, PhD

Associate Professor

Biochemistry

   
Peter Sykora, PhD

Lecturer, Adjunct

Biochemistry

   
Sona Vasudevan, PhD

Professor

Bioinformatics, Systems Medicine

   
Ken Wasserman, PhD

Assistant Professor

Biochemistry

Guest Lecturers

 
Name Title Expertise
   
Dan-Paul Hartmann, PhD  
 

Pathology

Dr. Hartmann had served as a Professor in the Department of Pathology and Scientific Director of Molecular Diagnostics Laboratory at Georgetown University Medical Center before he retired in 2017. Dr. Hartmann is an expert in the field of molecular diagnostics, with the specialization in techniques including FISH, tissue microarray, and PCR-based technologies, as well as CLIA and CAP-certification for diagnostic tests.

   
Stephen Hewitt, MD, PhD
 

Human Diagnostics

   
William Tu, PhD
 

Human Diagnostics

   
Kerry Scott, PhD
 

Human Diagnostics

   
Wyatt Vreeland, PhD

Research Chemical Engineer, National Institute of Standards & Technology

 
   
Mary Young, MD
 

Infectious Disease, HIV

   
Hang Yuan, PhD
 

HPV

Mentors

 
Name Title Expertise
   
Christopher Albanese, PhD

Professor

 
   
Partha Banerjee

Associate Professor

 
   
Jan Blancato, PhD

Professor

 
   
Robert Clarke, PhD

Professor

 
   
Albert Fornace, PhD

Professor

 
   
Eric Glasgow, PhD

Professor

 
   
Nady Golestaneh, PhD

Associate Professor

 
   
Bassem Haddad, PhD

Professor

 
   
Michael Johnson, PhD

Professor

 
   
Joanna Kitlinska, PhD

Associate Professor

 
   
Charbel Moussa, PhD

Associate Professor

 
   
Anna Riegel, PhD

Professor

 
   
Paul Roepe, PhD

Professor

Malaria

   
Rodney L. Rouse, DVM, MBA, PhD

Associate Director, Div. of Applied Regulatory Sciences, FDA/CDER

 
   
Rabindra Roy, PhD

Associate Professor

 
   
Ashot Shekoyan, MD, MS

Clinical Trials Manager

 
   
Geeta Upadhyay, PhD

Assistant Professor

 

Faculty

 
Name Title Expertise
   
Matthew Arnold, MS, MBA  

Instructor, Adjunct

Biopharma/Biotech Management

Vice President, Operations Therapy Area Leader (Oncology) at AstraZeneca/MedImmune
MBA from the University of Michigan
Matt leads the Oncology Therapy Area for Operations at AstraZeneca/MedImmune.  In this role he is accountable for developing and implementing supply chain strategies for all biologic and small molecule oncology products globally.
He previously served for three years as VP, Head of Operations for AstraZeneca’s small molecule biotech unit.  In this role he was responsible for drug development project management, strategic planning, scientific communications, research operations and facilities management of R&D sites in the UK, Sweden, Boston and Bangalore.  He also served as Secretariat for the AstraZeneca Board Science Committee.  Matt joined AstraZeneca via MedImmune, where he served as Vice President, Chief of Staff and was a member of the MedImmune Executive Team. 
Prior to MedImmune Matt spent 11 years with Amgen where he held roles in product development, supply chain risk management, international operations, licensing and human resources.  He began his career as an active duty naval officer, serving as commanding officer of a special operations ship, an engineering division officer and an instructor at the US Naval Academy. 
Matt holds a BS from the U.S. Naval Academy, a MS in Biochemistry and Molecular Biology from Georgetown University, and a MBA from the University of Michigan.

   
Robert Burleson, MBA  

Assistant Professor

Finance

CEO, IOMAXIS
Bob is currently the CEO of IOMAXIS. He has thirty years of operational, accounting, and financial experience encompassing active involvement in major strategic decisions. His background includes Acquisitions and Divestitures with proven leadership ability to manage the revenue generating employees of a company. He is highly skilled in strategic and financial planning for entrepreneurial concerns and companies up to $200 million.

   
Jack G. Chirikjian, PhD

Professor

Entrepreneurship

   
Sandeep Dahiya, PhD

Associate Professor

Finance

   
Charles Dormer, MA  

Lecturer, Adjunct

Leadership, Management

MS, MPhil, Organizational Dynamics, University of Pennsylvania. Hogan Assessment Certificatie, Corporate Coach International Program
Charles Dormer brings over 35 years of experience in healthcare and pharmaceutical R&D to his executive coaching and consulting work. He has worked for the some of top pharmaceutical companies including SmithKline Beecham, GlaxoSmithKline, Wyeth, Pfizer and AstraZeneca. Charles held a number of roles ranging from strategy definition and implementation, management, research, operations, reengineering, organization development, business redesign, portfolio and alliance management and chief of staff activities. He has been involved in major mergers and acquisitions within the pharmaceutical industry and major change efforts. 
Charles’ career transitioned to becoming an executive coach/consultant based on his passion for changing organizations and helping leaders to maximize their productivity and success, development leadership capabilities, and successfully manage change and uncertainty.
Find out more about Charles Dormer's business here.

   
Stephanie Duatschek, MBA, MS  

Lecturer, Adjunct

Biopharma/Biotech Commercialization

Principal, FlexIntellect, LLC
Based in the Washington, DC area, Stephanie has over 20 years’ experience in biopharmaceutical development.  Prior to becoming a consultant, Stephanie was Vice President of Commercial Operations for MedImmune (a subsidiary of Astra-Zeneca). Stephanie's career spans clinical development, regulatory, portfolio management, and alliance management:  she transitioned to the commercial organization in 2007.  During her tenure at MedImmune she; facilitated merger/operating model design in R&D and Commercial Operations; led product development teams; developed and implemented Design for Launch governance structure; and led strategic co-development alliances.   As a consultant Stephanie focuses on strategy (corporate and product) and organizational preparedness for new product launches.

   
Michael Gove, MS  

Lecturer, Adjunct

Business Development, Marketing

Independent Consultant
Michael Gove (Mike) is an independent consultant interested in effecting a positive outcome on workforce quality in biotechnology. He has over thirty years experience in commercial operations with a track record for driving growth. Mike served as Vice President of Marketing and Customer & Technical Service for ATCC, and held multiple positions at Life Technologies (Thermo Fisher), including Director of Marketing, Director of Immunology Venture, and Corporate Planning Manager. His experience includes creating and growing brands and customer equity through the commercialization of products and services. Mike offers a broad background in marketing, sales, business development and product management with a flair for navigating through difficult business environments to achieve business goals.

   
James Hawkins, MBA, PhD  

Associate Professor, Adjunct

Investment Banking

Managing Director, Focus Investment Banking
PHD, Molecular Biology, Baylor College of Medicine in Houston, Texas
James (Jim) W. Hawkins, MBA, PhD, is the Managing Director of Focus Investment Banking. He specializes in mergers and acquisitions and corporate finance in the Healthcare and Life Sciences sector. Prior to investment bank, Dr. Hawkins served as President and CEO of five early stage biotechnology companies and Chairman of a sixth and has had experience in all major areas of the biopharmaceutical industry.

   
Arthur House, JD

Lecturer, Adjunct

Intellectual Property

   
Richard Kjelgaard, JD

Lecturer, Adjunct

Intellectual Property

   
Michael Kowler

Lecturer, Adjunct

Finance

   
Larry Millstein, JD, PHD  

Professor

Intellectual Property

Director, Millen, White, Zelano & Branigan, PC
PHD, Chemistry, University of California at San Diego
Larry Millstein is Director of the law firm Millen, White, Zelano & Branigan which serves a wide variety of clients, large and small, on legal matters relating to biotechnology and intellectual property. After receiving his law degree, Larry worked as a patent agent and then an attorney with the law firm of Foley & Lardner,. He later served as Senior Patent Counsel with Human Genome Sciences. Subsequently he formed the law firm of Millstein & Taylor where he practiced biotechnology patent law for over a decade. When Millstein & Taylor merged with Holland & Knight, he became a partner and head of the Holland & Knight biotechnology practice.
Find out more about Larry Millstein's law firm here.

   
Clifford Mintz, PHD

Professor, Adjunct

Regulatory Affairs

   
Mark Mlynarczyk, MA

Lecturer, Adjunct

Biopharma Management

   
Hartwell (Phil) Philips, CPA  

Lecturer, Adjunct

Finance

Phil is a retired Partner in the accounting firm of CohnReznick LLP. He has forty years of experience in the application of generally accepted accounting principles and federal and state income tax planning and compliance. His focus as a CPA was auditing, tax planning and business consulting for companies in the industries of government contracting, technology and the storage and distribution of jet aviation fuel for the Airlines for America. In addition, he is knowledgeable of federal cost accounting principles and led his firm’s training programs for many years.

   
Matthew Portnoy, PHD  

Associate Professor, Adjunct

Government Program Management

NIH SBIR/STTR Program Manager and Director, Division of Special Programs, Office of Extramural Programs, Office of Extramural Research, Office of the Director, NIH
Ph.D., Biochemistry and Molecular Biology, Johns Hopkins University School of Public Health
Dr. Matthew Portnoy is the NIH SBIR/STTR Program Manager and Director, Division of Special Programs, Office of Extramural Programs, Office of Extramural Research, Office of the Director, NIH. In this role, he manages the SBIR/STTR programs at NIH, coordinates the 24 NIH Institutes/Centers that receive funding for the programs and across HHS. Additionally, as the Director, Division of Special Programs, Dr. Portnoy and his staff provide scientific program management and oversight of the Academic Research Enhancement Award (AREA) Program, and support for conferences and scientific meetings (R13/U13) and ensures that NIH extramural staff are trained to meet the ever-changing demands of their job.

   
Stephen Sullivan  

Lecturer, Adjunct

Entrepreneurship

Founder, CRO Advisors, LLC
Sullivan was President and CEO of Harlan Laboratories, a major pre-clinical CRO from 2006-2010. From 1999-2006 he headed most of the clinical divisions of Covance, Inc. Prior to Covance, Sullivan was Chairman, President and Chief Executive Officer of Xenometrix, Inc., a drug discovery tool company. Previously, He served in several senior management positions at Abbott Laboratories, including Vice President of Worldwide Marketing for Abbott Diagnostics, and Vice President and General Manager of the Diagnostic Assay Sector and also held senior management positions at Lyphomed, Inc., Dart and Kraft Inc., and Baxter International.

   
Sarah Tanksley, MS  

Lecturer, Adjunct

Regulatory Affairs

Presdient & CEO, Tanksley Consulting Group, LLC
MS Regulatory Science, Johns Hopkins University
Sarah Tanksley has over 15 years of laboratory and regulatory experience with both the NIH and FDA. She is an expert on a wide range of issues related to the FDA's regulatory requirements: Warning letters and consent decree remediation, Data integrity remediation, Mock inspections, 21 CFR 211 and Deviation and laboratory investigations. Sarah’s past experiences includes Principal Consultant of Strategic Compliance with PAREXEL Consulting, Reviewer/Inspector with the Office of Compliance, Center for Biologics Evaluation and Research, FDA, and research lab experience within the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and the U.S. Military. Sarah currently teaches cGMP Compliance and Regulatory Affairs at GUMC.

Guest Lecturers

 
Name Title Expertise
   
Russell Boyd, PhD, PMP

Head of Operational Excellence, Global Medicines Development, AstraZeneca

 
   
Kimbell Duncan, MS, PhD Candidate

Founder & Director, Rush Charitable Foundation

Investment Banking

   
Justin Eggleton

Director of Regulatory Affairs, MCRA

Medical Device Reguations

   
Steve Ferguson

Technology Transfer, NIH

 
   
Anderson Gaweco, MD, PhD

President & CEO, Innovimmune Biotherapeutics

ImmunoOncology

   
Jay George, PhD

Principal Investigator, Amelia Technologies

SBIR, STTR

   
Deb Neivert, MBA  

Head of Portfolio Analytics, Pipeline Strategy and Management, AstraZeneca

 

Head of Portfolio Analytics
MBA from Duke University
Deb Neivert was appointed Head of Portfolio Analytics in May 2017. In this role, she is responsible for quarterly portfolio reviews to the senior executive team, therapy area analytics and building out the capacity and resource capability in the Global Medicines Development function. Her previous responsibilities included Head of CVMD Pipeline Strategy where she helped build the therapeutic area strategy across the early and late science units, as well as portfolio prioritization analysis and recommendations to senior executives on the CVMD pipeline assets. She also worked in Commercial Early Assets teams in Infectious Disease, Vaccines, Cardiovascular, and Neuroscience Therapeutic Areas. Deb was responsible for commercial guidance of development strategies across these TAs, as well as for commercial evaluation of business development opportunities. Prior to that she worked in late-stage and inline brands, leading product launches in a variety of product categories.
In addition to expertise across TAs and modalities, Deb has nearly 20 years of healthcare experience spanning commercial business functions, four in sales, 15 in marketing, 3 in portfolio and one in managed care-- having spent the last eleven years at /AstraZeneca/ MedImmune with previous work at Eli Lilly and Company, Parke-Davis and BlueCross/BlueShield of NC.
Deb received her MBA from Duke University, where she graduated with top honors, and her undergraduate degree in Biology and Economics from the University of Pennsylvania.

   
Mark Pomerantz

Principal, Pomerantz & Son

Finance

   
Salim Shah, PHD
   
   
Aiman Shalabi  

Chief Medical Officer, Cancer Research Institute

 

Chief Medical Officer at the Cancer Research Institute (CRI)
Aiman Shalabi is a global executive with over 20 years’ experience in driving new treatments for patients with cancer. Aiman’s key strength is aligning multiple stakeholders in areas of complex science to develop a common vision and execute against that vision. He is currently the Chief Medical Officer at the Cancer Research Institute (CRI) where he provides strategic direction and integrated oversight for CRI’s cancer immunotherapy clinical trial program. Previously, Aiman was the Vice President, Global Medical Affairs group for Immune Oncology at AstraZeneca and was also the Global Product Vice President at AstraZeneca leading the cross-functional development team for PD-L1 from first in human through phase III. He also led multiple other Immuno-oncology programs at MedImmune the in-licensing and development of Tremelimumab (from Pfizer) and OX40 and importantly – initiated the IO combinations studies early in the development cycle. He also served as the chair of the Joint Steering Committee and implemented novel external collaborations with the Cancer Research Institute, Friends of Cancer Research, SWOG, NCIC (Canada) and the National Cancer Institute (US).

   
Andrew Skibo  

Head, Global Biologics Operations, AstraZeneca

 

Head of Global Biologics Operations for AstraZeneca
Master of Science degree in Chemical Engineering
Andrew D. Skibo is currently Head of Global Biologics Operations for AstraZeneca. He has over 40 years of experience in international pharmaceutical work in both small molecule and biologics, including 35 years specifically in biologics. Andy has related experience with both operating companies (Amgen, Genentech, Monsanto) and large international engineering and construction firms specializing in this business (Foster Wheeler, Life Sciences, Fluor). Andy served as Chairman of the Board and as a member of the Executive Committee of ISPE. He is Past Chairman of the Global Pharmaceutical Manufacturing Leadership Forum. Andy is a member of the Editorial Advisory Board of Life Science Leader Magazine. He has published or presented over 80 articles in this field and is a sought-after keynote speaker. Andy holds a Master of Science degree in Chemical Engineering and a Bachelor of Science degree in Chemistry, both from the Massachusetts Institute of Technology.

   
Bill Snider

Partner, BroadOak Investment Bank

Venture Capital Funding

   
Mike Stepp

Principal, Hudson Pacific (CHECK)

 
   
Keith Tode

VP, MCRA

Business Development, Medical Device

Mentors

 
Name Title Expertise
   
ia Agnostio, MS

Director of Business Development, Immunomix Therapeutics

 
   
Steve Birnbaum

Director of Business Development, Tissue Gene, Inc.

 
   
Peter Frantz, MBA, MS

Director of Business Development, Amarex Inc.

 
   
William Kelly

President, BioInformatics, LLC

 
   
Ruchika Nijhara

Director Technology Transfer, Georgetown Office of Technology Commercialization

Technology Transfer

   
Faye O’Brien

Metrics & Performance Lead, AstraZeneca

 
   
Selen Oztunaoglu, MS

CEO, Nexus, LLC

 
   
Anurag Patnaik, MS

Ceres NanoScience

 
   
Jason Rose, MD

CEO, Globin Solutions

 
   
Michael Scott

Global Supply Strategy Director, AstraZeneca

 
   
Edward Steele

Chairman, EAS Consulting

 
   
Kam To, PhD

CEO, GeneWhisper